Advances in Vaccine Development of the Emerging Novel Genotype Fowl Adenovirus 4

Aijing Liu, Yu Zhang, Hongyu Cui, Xiaomei Wang, Yulong Gao* and Qing Pan*

State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, China, 2 Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Disease and Zoonoses, Yangzhou University, Yangzhou, China

Fowl adenovirus (FAdV) was first reported in Angara Goth, Pakistan, in 1987. For this reason, it is also known as "Angara disease." It was later reported in China, Japan, South Korea, India, the United States, Canada, and other countries and regions, causing huge economic losses in the poultry industry worldwide. Notably, since June 2015, a natural outbreak of severe hydropericardium hepatitis syndrome (HHS), associated with a hypervirulent novel genotype FAdV-4 infection, has emerged in most provinces of China. The novel virus FAdV-4 spread rapidly and induced a 30-100% mortality rate, causing huge economic losses and threatening the green and healthy poultry breeding industry. Vaccines against FAdV-4, especially the emerging novel genotype, play a critical role and will be the most efficient tool for preventing and controlling HHS. Various types of FAdV-4 vaccines have been developed and evaluated, such as inactivated, live-attenuated, subunit, and combined vaccines. They have made great contributions to the control of HHS, but the details of cross-protection within FAdVs and the immunogenicity of different vaccines require further investigation. This review highlights the recent advances in developing the FAdV-4 vaccine and promising new vaccines for future research.

Keywords: HHS, vaccine advances, emerging, FAdV-4, novel genotype

INTRODUCTION

Fowl adenovirus (FAdV) belongs to the family Adenoviridae and genus Aviadenovirus and is further divided into five species (FAdV-A-E) with 12 serotypes (FAdV-1-8a, 8b-11) based on the profile of restriction enzyme digestion and sera cross-neutralization assay according to the guidelines of the International Committee on Taxonomy of Viruses (1). FAdVs are capable of infecting various birds, such as chickens (2, 3), ducks (4–6), geese (7), pigeons (8), peacocks (9), and other wild birds, inducing severe clinical symptoms or potential infection. FAdVs show different tropisms for multiple organs and are associated with several high-impact poultry diseases, such as hydropericardium-hepatitis syndrome (HHS), inclusion body hepatitis (IBH), and gizzard erosion (GE). FAdV infection associated with HHS, IBH, and GE has been reported worldwide and induces huge economic losses in the poultry industry.
HHS associated with serotype 4 fowl adenovirus (FAdV-4) infection was first found and reported in Angara Goth, a region of Pakistan, in 1987, so the disease is also known as “Angara disease” (10). It was later reported in China (3, 11), Japan (12, 13), South Korea (14), India (15), the United States (16), Canada (17), and other countries and regions, causing huge economic losses in the poultry industry worldwide. Notably, since June 2015, a natural outbreak of severe HHS associated with a hypervirulent novel genotype FAdV-4 infection has emerged in most provinces of China (3, 11). The novel genotype FAdV-4 spread rapidly and induced a 30-100% mortality rate, causing huge economic losses and threatening the green and healthy poultry breeding industry. Furthermore, co-infections of FAdV-4 with other virus further aggravate the harmfulness of the disease (18–20).

Currently, various types of vaccines have been developed and evaluated to control HHS, and several inactivated combined vaccines have been licensed and produced by commercial companies, which have made important contributions to the poultry industry. Given the ability to deliver foreign adenovirus genes, natural non-pathogenic FAdV-4 (16) and artificial attenuated FAdV-4 (17) have developed efficient vaccine vectors, which protect chickens against HHS and significantly reduce the cost of the combined vaccine. This brief review summarizes vaccine development efforts using inactivated viruses, live-attenuated viruses, subunit antigens, and combined vaccines against FAdV-4, especially novel FAdV-4.

Inactivated Monovalent Vaccines

Traditional inactivated vaccine immunization remains the main preventive method for some poultry diseases, especially emerging viruses such as SARS-CoV-2 (21, 22). Given the emergence of the hypervirulent novel genotype FAdV-4, inactivated vaccine immunization remains the main prevention method, having the advantages of safety, cost-saving, good humoral immunity effect, and low influence by maternal antibodies. For the emerging HHS, Pan et al. isolated and identified the HLJFAd15 strain as a novel hypervirulent FAdV-4 from the field layers with HHS in China in 2015 (2). Subsequently, SPF chickens were immunized with an inactivated oil-emulsion FAdV-4 vaccine formulated with the HLJFAd15 strain, and the vaccine’s protective effect was evaluated (23). The results indicated that the vaccine could provide a high-level antibody, preferential T helper 2 (Th2) response, and full protection against a lethal dose of novel hypervirulent FAdV-4. Similarly, the novel genotype SDJN0105 strain (24), HN strain (25), and CH/GZXF/1602 strain (26) developed an inactivated vaccine, and all vaccines induced high levels of antibodies and showed sufficient protection for chickens from HHS.

Du et al. attempted to develop vaccines from both embryo-adapted and cell culture-derived viruses to optimize the manufacturing technique of inactivated vaccines (25). The results showed no mortality in either of the immunized groups in the challenge experiment. However, cell-culture-derived vaccines could induce earlier and higher humoral immune responses and no lesions appeared, but IBH was observed in the embryo-adapted derived vaccine, indicating that cell-culture-derived vaccines could be a better candidate to control emerging HHS.

For cross-protection of the FAdV-4 inactivated vaccine, Kim et al. developed an inactivated vaccine with a traditional FAdV-4 strain K531/07 and evaluated the cross-protection of the vaccine against various serotypes of FAdV causing IBH or HHS, including serotypes 5, 8a, 8b and 11 (27). They found that the inactivated FAdV-4 vaccine could provide cross-protection against various serotypes of FAdV in vaccinated chickens and progenies of vaccinated breeders, indicating that the FAdV-4 vaccine could be an effective candidate for the prevention of IBH and HHS. Furthermore, Xia et al. prepared an inactivated vaccine using a novel genotype FAdV-4 strain CH/GZXF/1602, and the immunogenicity evaluation results showed that the FAdV-4 vaccine could protect chickens against both virulent FAdV-4 and virulent FAdV-8b (26).

Notably, all inactivated vaccines were derived from wild-type virulent FAdV-4 strains. As biosafety threats of inactivated vaccines from potential pathogenic components have been presented to the poultry industry, safer vaccines are urgently needed. Zhang et al. replaced the virulent vaccine formulation with an artificial non-pathogenic FAdV-4 strain rHN20 using a reverse genetic technique and developed a novel inactivated oil-adjuvanted vaccine derived from the rHN20 strain (28). The results showed that the vaccine-induced high titers of neutralizing antibodies provided full protection from a lethal dose of virulent FAdV-4 challenge and significantly reduced potential biosafety threats. The details of inactivated vaccines are summarized in Table 1.

Live-Attenuated Monovalent Vaccines

For the traditional genotype FAdV-4, Schonewille et al. developed an attenuated FAdV-4 vaccine by adapting a pathogenic virus to the QT35 cell line, and no clinical signs or mortality were observed in birds challenged with the attenuated virus (29). Although enzyme-linked immunosorbent assay (ELISA) and neutralization tests indicated a weak antibody response in some birds following immunization with the live vaccine, the vaccine provided full protection against the challenge, which is an interesting phenomenon for FAdVs.

For the novel genotype FAdV-4, Zhang et al. identified the critical gene and amino acid (aa) for virus virulence (30), subsequently, two non-pathogenic strains, rHN20 and rR188I, were rescued by the reverse genetic technique based on the fosmid system. rHN20 caused no clinical signs or mortality, indicating that hexon determines the virulence of FAdV-4. Furthermore, Zhang et al. identified aa 188R of hexon as the critical aa for virulence of the novel genotype FAdV-4, and the rR188I strain also showed no pathogenicity in SPF chickens. The immunogenicity of both rHN20 (28) and rR188I (30) was evaluated in SPF chickens when they were used as live-attenuated vaccines. Chickens inoculated with different doses and routes of rHN20 or rR188I produced high levels of neutralizing antibodies and were fully protected against a lethal dose challenge of the pathogenic novel genotype FAdV-4. Furthermore, the immunized groups showed no clinical
TABLE 1 | List of inactivated and live-attenuated vaccines against FAdV-4.

| Strain               | Origin     | Adjuvant | Dosage (/bird) | Immune route | Survival rate (%) |
|----------------------|------------|----------|----------------|--------------|-------------------|
| HUJFAd15             | CEL*       | Oil      | 10^5 TCID_{50} | IM           | 100               |
| CH/GZXF/1602         | CEL*       | Oil      | 4.5×10^6 TCID_{50} | H\(^{P}\)   | 100               |
| SDNO1014             | CEF*       | Oil      | 10^5 TCID_{50} | IM           | 100               |
| HN                   | LMH\(^{f}\) | Oil      | 10^5 TCID_{50} | H\(^{P}\)   | 100               |
| HN                   | CE*        | Oil      | 10^5 TCID_{50} | H (80%)     | 100               |
| KS31/07              | CEL        | Sepica ISA 70 | 5×10^3 TCID_{50} | IM           | 80                |
| rHN20                | LMH        | Oil      | 3×10^6 PFU     | IM           | 100               |
| rHN20                | LMH        | Oil      | 3×10^7 PFU     | H           | 100               |

| Strain               | Origin     | Adjuvant | Dosage (/bird) | Immune route | Survival rate (%) |
|----------------------|------------|----------|----------------|--------------|-------------------|
| FAdV-4/QT3S          | QT3S       | Oil      | 5×10^4 TCID_{50} | IM           | 100               |
| rR188I               | LMH        | Oil      | 10^6 PFU       | IM           | 100               |
| rHN20                | LMH        | Oil      | 10^6 PFU       | IN           | 100               |
| rHN20                | LMH        | Oil      | 10^6 PFU       | H            | 100               |
| FAdV4-RFP_F1         | LMH        | Oil      | 2×10^6 TCID_{50} | IM           | 100               |
| FA4-EGFP             | LMH        | Oil      | 10^6 TCID_{50} | IM           | 100               |
| FAdV4-EGFP-rF2       | LMH        | Oil      | 2.5×10^6 TCID_{50} | IM           | 100               |

*Chicken embryo liver cells.
*Chicken embryo kidney cells.
*Leghorn male hepatocellular cells.
*Chicken embryo.
*Intramuscular.
*Subcutaneous.
*Intranasal.

Symptoms or histopathological changes, and the viral load was significantly lower after the challenge.

Not only was the hexon-edited virus significantly attenuated, but the fiber-1 and fiber-2 edited viruses were rescued and identified as non-pathogenic to SPF chickens. Mu et al. rescued the recombinant virus FAdV4-RFP_F1 via the CRISPR/Cas9 technique, which contained a fusion protein of RFP and fiber-1 (31). The recombinant virus was efficiently attenuated and provided full protection against the lethal challenge of FAdV-4, demonstrating that fiber-1-edited FAdV4-RFP_F1 could be a live-attenuated vaccine candidate and fiber-1 could be a potential insertion site for novel vaccine development. In addition, Xie et al. generated a recombinant virus F4-EGFP expressing EGFP-fiber-2 fusion protein via the CRISPR/Cas9 technique (32). FA4-EGFP caused no clinical signs or mortality in chickens, indicating that the virus was significantly attenuated.

Moreover, FA4-EGFP could also provide efficient protection against a lethal dose challenge, suggesting that fiber-2 edited FA4-EGFP is a vaccine candidate and a potential insertion site for delivering foreign antigens. Furthermore, Xie et al. replaced the fiber-2 gene with egfp and rescued FAdV-4-EGFP-rF2, which could efficiently replicate in LMH-F2 cell lines expressing fiber-2 protein (33). FAdV-4-EGFP-rF2 was highly attenuated and provided full protection against the pathogenic FAdV-4 challenge. The FAdV-4-EGFP-rF2 vaccine-induced neutralizing antibodies are at the same level as FA4-EGFP. The details of live-attenuated monovalent vaccines are summarized in Table 1.

**Subunit Monovalent Vaccines**

Subunit vaccines are safer than vaccines based on the whole virus in production and vaccination procedures, and researchers have made important efforts to develop subunit vaccines against FAdV-4. Different subunit antigens, expression systems, and adjuvants have been evaluated to develop FAdV-4 subunit vaccines.

Before the novel genotype FAdV-4, several studies tried to develop a subunit vaccine of the traditional genotype FAdV-4. Shah et al. utilized a prokaryotic expressed structure protein penton base coupled with Freund’s complete adjuvant (FCA) to develop a subunit vaccine that showed 90% protection for chickens (34). Aziz et al. evaluated both the prokaryotic expressed full-length and epitope-focused 1-225 aa of penton formulated with Montanide ISA 71VG adjuvant, and both vaccines showed protection rates of 50% (35). Schachner et al. compared the immunogenicity of different capsid proteins of FAdV-4, including fiber-1, fiber-2, and L1 region of hexon (L1-hexon) (36). Fiber-1, fiber-2, and L1-hexon were simultaneously expressed in the baculovirus system and composed of GERBU Adjuvant LQ no.3000, and fiber-2 (27/28) showed better protection efficacy than fiber-1 (16/26) and L1-hexon (7/26), highlighting that fiber-2 might be an ideal antigen component for subunit vaccine development. Shah et al. first tried a prokaryotic-expressed non-structural protein 100 K of FAdV-4 coupled with FCA; unfortunately, it showed only a 40% protection rate (37).

Although HHS associated with a novel genotype FAdV-4 emerged in 2015, great progress has been made in subunit vaccine development. Wang et al. tested the efficacy of FAdV-4 surface protein fiber-1, fiber-2, L1-hexon, and penton base expressed in Escherichia coli and formulated with FCA (38). The results indicated that fiber-2 (50 µg/bird) and fiber-1 (100 µg/bird) could induce complete protection, while protection of the L1-hexon and penton bases could induce considerable protection at high dosages but not completely. The good immunogenicity of prokaryotic expressed fiber-2 was further confirmed when fiber-2 was coupled with different adjuvants, such as FCA (39), Montanide ISA 71VG (40), and Sigma adjuvant (41), respectively. However, fiber-1 showed better protection than fiber-2 when expressed in a eukaryotic system, although the protection rates of both fiber-1 and fiber-2 were higher than those of the penton base (42). Wang et al. utilized a commercial adenovirus vector to express antigens in HEK293 cells, and the antigen was assembled into a penton-
dodecahedron (Pt-Dd), which provided 100% protection (42). Jia et al. constructed a recombinant Lactococcus lactis and Enterococcus faecalis expressing truncated hexon protein or fused with a dendritic cell-targeting peptide, which was orally immunized and induced protection rates varying from 50 to 90% (43). These studies provide a solid theoretical basis for the research and development of subunit vaccines.

In addition, several studies have been conducted to obtain many results. Yin et al. constructed a pVAX1-Fiber2 DNA vaccine, but the protection was also insufficient (60%) for the novel genotype FAdV-4, and the above studies require further optimization (41). Nevertheless, many improvements have achieved good results. Hu et al. developed a fusion subunit antigen of fiber-2 (Gly275- Pro479) and hexon (Met21-Val51) that was capable of providing full protection for chickens (44). Tufail et al. displayed several highly conserved epitopic regions of hexon on the virus-like particle (VLP) of the core protein of the hepatitis B virus (45). The VLP vaccine containing Asp348-Phe369, Ser19-Pro82, and Gly932-Phe956 confer 90%, 70%, and 40% protection. The details of subunit vaccines against FAdV-4 are summarized in Table 2.

### Combined Vaccines

Adenovirus, especially the commercial human adenovirus, is an efficient and stable delivery carrier widely used for gene therapy (46) and vaccines against emergent viruses, such as Ebola (47) and SARS-CoV-2 (48). With gene editing and reverse genetic technology, the emerging novel genotype, FAdV-4, has been successfully modified as a viral vector and applied to construct combined vaccines. Pan et al. firstly developed a novel genotype, FAdV-4, and identified the natural large genomic 1966bp deletion as a foreign gene insertion site (49). Mu et al. also optimized the CRISPR/Cas9 operating platform to insert a foreign gene into the fiber gene of FAdV-4 (31). Meanwhile, Yan et al. established an easy-to-use reverse genetics system based on Gibson assembly to modify the right and partial left genes (50). Pei et al. developed an infectious clone based on cosmid and found that ORF16 and 17 were important for virus

### Table 2 | List of subunit vaccines against FAdV-4.

| Antigen   | Strain          | Expression system | Dosage (/bird) | Adjuvant         | Immune route | Survival rate (%) |
|-----------|-----------------|-------------------|----------------|------------------|--------------|------------------|
| penton    | PR-06           | E. coli           | 25 µg          | FCA              | H            | 90               |
| penton    | NIAB/NIBGE 01   | E. coli           | 100 µg         | Montanide ISA 71VG | H            | 70               |
| penton    | (1-225 aa)      |                   | 100 µg         | Montanide ISA 71VG | H            | 50               |
| fiber-1   | KR5             | Baculovirus       | 50 µg          | GERBU Adjuvant LQ no.3000 | IM | 61.5             |
| fiber-2   | KR5             | Baculovirus       | 50 µg          | GERBU Adjuvant LQ no.3000 | IM | 96.4             |
| L1-hexon  | KR5             | Baculovirus       | 50 µg          | GERBU Adjuvant LQ no.3000 | IM | 26.9             |
| 100K      | NIAB/NIBGE 01   | E. coli           | 25 µg          | FCA              | H            | 40               |
| fiber-1   | SXD15           | E. coli           | 100 µg         | FCA              | IM            | 100              |
| fiber-2   | SXD15           | E. coli           | 50 µg          | FCA              | IM            | 75               |
| fiber-2   | SXD15           | E. coli           | 50 µg          | FCA              | IM            | 100              |
| fiber-2   | SXD15           | E. coli           | 50 µg          | FCA              | IM            | 70               |
| fiber-2   | SXD15           | E. coli           | 50 µg          | FCA              | IM            | 35               |
| fiber-2   | SXD15           | E. coli           | 2.5 µg         | FCA              | H            | 100              |
| fiber-2   | SXD15           | E. coli           | 10 µg          | Montanide ISA 71VG | IM | 100              |
| fiber-2   | SXD15           | E. coli           | 150 µg         | Sigma            | IM            | 100              |
| fiber-2   | SXD15           | E. coli           | 100 µg         | Sigma            | IM            | 100              |
| fiber-2   | SXD15           | E. coli           | 50 µg          | Sigma            | IM            | 80               |
| fiber-1   | SXD15           | Ad-HK2            | 0.5 µg         | N/A              | IM            | 100              |
| fiber-2   | SXD15           | Ad-HK2            | 0.5 µg         | N/A              | IM            | 80               |
| penton    | SXD15           | Ad-HK2            | 0.5 µg         | N/A              | IM            | 67.7             |
| PtDd       | SXD15           | Ad-HK2            | 0.5 µg         | N/A              | IM            | 100              |
| DC-hexon  | GX01            | L. lactis         | 10⁹ CFU        | N/A              | O            | 60               |
| hexon     | GX01            | L. lactis         | 10⁹ CFU        | N/A              | O            | 50               |
| DC-Hexon  | GX01            | E. faecalis       | 5x10⁹ CFU      | N/A              | O            | 90               |
| hexon     | GX01            | E. faecalis       | 5x10⁹ CFU      | N/A              | O            | 80               |

*a: Amino acid.
*b: Loop 1 region of hexon.
*c: Penton-dodecahedron.
*d: DC-Hexon: hexon fused with dendritic cell targeting peptide.
*e: Escherichia coli.
*f: Lactococcus lactis.
*g: Enterococcus faecalis.
*h: Freund’s complete adjuvant.
*i: Subcutaneous.
*j: Intramuscular.
+k: Oral.
+l: Not applicable.
replication and unsuitable for foreign gene insertion (51). Finally, Pan et al. built a reverse genetic technique based on the fosmid system to operate the genome of the novel genotype FAdV-4 and further identified 10 ORFs at the left end and 13 ORFs at the right end of the novel FAdV-4 as non-essential regions for virus replication, which provided a good foundation for foreign gene delivery (52).

Virulence weakening is critical for vector development because of the high pathogenicity of the novel genotype FAdV-4. Zhang et al. first identified the critical gene and key aa for the virulence of the novel FAdV-4 (30) and subsequently obtained the non-pathogenic strain rHN20, posting the basis for development and application. Subsequently, the immunogenetic VP2 gene of the very virulent infectious bursal disease virus (vIvBDV) was inserted into the natural 1966Del deletion site and induced complete protection in chickens against both the novel genotype FAdV-4 and vIvBDV challenge when used as an inactivated vaccine (53) or live vectored vaccine (52). Lu et al. inserted a FAdV-8b fiber into the fiber-2 position of FAdV-4, which simultaneously protected chickens from novel genotype FAdV-4 induced HHS and FAdV-8b induced IBH (54).

In addition to the above FAdV-4 vectored vaccines, several other combined vaccines were evaluated and showed good effects. Luca et al. constructed a chimeric fiber protein (crecFib-4/11) capable of simultaneously protecting chickens against HHS and IBH (55), highlighting a new concept: chimeric fiber proteins can be extended across viral species. Tian et al. developed a recombinant Newcastle disease virus (NDV) LaSota vaccine strain expressing fiber-2 of FAdV-4 (rLaSota-fiber2) and live and inactivated vaccines derived from rLaSota-fiber2 (56). Both vaccines provided complete protection against virulent NDV. However, the live rLaSota-fiber2 vaccine provided better protection against the FAdV-4 challenge than the inactivated vaccine, indicating that the NDV-vectored FAdV-4 vaccine is a promising bivalent vaccine candidate to control both HHS and ND.

**CONCLUSIONS**

Although various vaccines against the novel genotype FAdV-4 have been developed, and great progress has been made in controlling emerging HHS, many studies need further investigation. Preliminary evaluation of the inactivated vaccine derived from the traditional genotype FAdV-4 has been conducted in cross-protection with other serotypes of FAdV, but cross-protection vaccines based on the novel genotype FAdV-4 need systemic analysis within different serotypes of FAdV. Furthermore, the FAdV-4 vaccine vector needs to be deeply explored as an efficient vector to deliver multiple foreign antigens to reduce vaccine costs further. Meanwhile, studies on novel vaccine adjuvants, subunit antigens, and new vaccines such as DNA or mRNA vaccines against the novel genotype FAdV-4 have been limited, and more research is needed on the control of HHS.

**AUTHOR CONTRIBUTIONS**

QP and YG conceived of and designed the study. AL and YZ conducted the literature search, analysis, and draft-writing. HC and XW helped write the research questions in the first draft and the modifications. All the authors contributed to the study and approved the final manuscript for publication.

**FUNDING**

This study was supported in part by the National Natural Science Foundation of China (32072879), the China Agriculture Research System (CARS-41-G15), and the Natural Science Foundation of Heilongjiang Province (TD2019C003).

**REFERENCES**

1. Steer PA, Kirkpatrick NC, O’Rourke D, Noormohammadi AH. Classification of Fowl Adenovirus Serotypes by Use of High-Resolution Melting-Curve Analysis of the Hexon Gene Region. *J Clin Microbiol* (2009) 47:311–21. doi: 10.1128/jcm.01567-08

2. Pan Q, Liu L, Wang Y, Zhang Y, Qi X, Liu C, et al. The First Whole Genome Sequence and Pathogenicity Characterization of a Fowl Adenovirus 4 Isolated From Ducks Associated With Inclusion Body Hepatitis and Hydropericardium Syndrome. *Avian Pathol* (2017) 46:571–78. doi: 10.1080/03079457.2017.1311006

3. Liu Y, Wan W, Gao D, Li Y, Yang X, Liu H, et al. Genetic Characterization of Novel Fowl Aviadenovirus 4 Isolates From Outbreaks of Hepatitis-Hydropericardium Syndrome in Broiler Chickens in China. *Emerg Microbes Infect* (2016) 5:e117. doi: 10.1038/emi.2016.115

4. Pan Q, Yang Y, Shi Z, Liu L, Gao Y, Qi X, et al. Different Dynamic Distribution in Chickens and Ducks of the Hypervirulent, Novel Genotype Fowl Adenovirus Serotype 4 Recently Emerged in China. *Front Microbiol* (2017) 8:1005. doi: 10.3389/fmicb.2017.01005

5. Chen H, Dou Y, Zheng X, Tang Y, Zhang M, Zhang Y, et al. Hydropericardium Hepatitis Syndrome Emerged in Cherry Valley Ducks in China. *Transbound Emerg Dis* (2017) 64:126–67. doi: 10.1111/tbed.12500

6. Tang Z, Liu M, Gao Z, Li M, Cao J, Ye H, et al. Pathogenicity and Virus Shedding Ability of Fowl Adenovirus Serotype 4 to Ducks. *Vet Microbiol* (2022) 264:109302. doi: 10.1016/j.vetmic.2021.109302

7. Wei Z, Liu H, Diao Y, Li X, Zhang S, Gao B, et al. Pathogenicity of Fowl Adenovirus (FAdV) Serotype 4 Strain SDJN in Taizhou Geese. *Avian Pathol* (2019) 48:477–85. doi: 10.1080/03079457.2019.1625305

8. Hess M, Prusas C, Vereecken M. And De Herdt P Isolation of Fowl Adenoviruses Serotype 4 From Pigeons With Hepatic Necrosis. *Berl Munch Tierarztl Wochenschr* (1998) 111:140–2.

9. Wang X, Li D, Deng Y, Yang X, Li Y, Wang Z, et al. Molecular Characterization and Pathogenicity of a Fowl Adenovirus Serotype 4 Isolated From Peacocks Associated With Hydropericardium Hepatitis Syndrome. *Infect Genet Evol* (2021) 90:104766. doi: 10.1016/j.meegid.2021.104766

10. Afzal M, Munee R. And Stein G Studies on the Aetiology of Hydropericardium Syndrome (Angara Disease) in Broilers. *Vet Rec* (1991) 128:591–3. doi: 10.1136/vr.128.25.591

11. Ye J, Liang G, Zhang J, Wang W, Song N, Wang P, et al. Outbreaks of Serotype 4 Fowl Adenovirus With Novel Genotype, China. *Emerg Microbes Infect* (2016) 5:e50. doi: 10.1038/emi.2016.50

12. Del Valle FP, Camba SI, Umali DV, Sasai K, Shiroti K, Katoh H, et al. Research Note: Molecular and Pathologic Characterization of Avian
Adenovirus Isolated From the Oviducts of Laying Hens in Eastern Japan. *Poultry Sci* (2020) 99:2459–68. doi: 10.1637/ps.2019-02.059

13. Maseki, Tada, Y. Jiski H, And Watanabe S. Genetic Characterization of a Fowl Adenovirus Serotype 4 Strain Isolated From a Chicken With Hydropericardium Syndrome in Japan. *Arch Virol* (2022) 167:1191–95. doi: 10.1007/s00705-022-05390-1

14. Lai YM, Min K, Lai HTL. And Mo J. Epidemiology of Fowl Adenovirus (FavD) Infections in South Korean Chickens During 2013-2019 Following Introduction of FavD-4 Vaccines. *Avian Pathol* (2021) 50:182–89. doi: 10.1080/03079457.2021.1872766

15. Chitradevi S, Sukumar K, Suresh P, Balasubramaniam GA. And Kannan D. Molecular Typing and Pathogenicity Assessment of Fowl Adenovirus Associated With Inclusion Body Hepatitis in Chicken From India. *Vet Anim Health Prod* (2021) 53:412. doi: 10.1007/s11250-021-02851-8

16. Mete A, Armien AG, Rejmanek D, Mott M, Crossley BM. Emergence of Fowl Aviadenovirus C-4 in a Backyard Chicken Flock in California. *J Vet Diagn Invest* (2021) 33:806–9. doi: 10.1371/journal.pone.0077601

17. Gregú, H, Poljak Z, Sharif S. And Nagy E. Pathogenicity and Cytokine Gene Expression Pattern of a Serotype 4 Fowl Adenovirus Isolate. *PloS One* (2013) 8:e77601. doi: 10.1371/journal.pone.0077601

18. Liu J, Shi X, Lv L, Wang K, Yang Z, Li Y, et al. Characterization of Co-infection With Fowl Adenovirus Serotype 4 and 8a. *Front Microbiol* (2021) 12:771805. doi: 10.3389/fmicb.2021.771805

19. Xu AH, Yang Y, Gao Y, Qi X, Liu C, Zhang Y, et al. An Inactivated Novel Fowl Adenovirus Serotype 4 Protects Chickens Against the Highly Pathogenic Serotype 4 Fowl Adenovirus. *Vet Res* (2021) 52:325. doi: 10.1186/s13567-021-00990-z

20. Yan T, Zhu S, Wang H, Li C, Diao Y. And Tang Y. Synergistic Pathogenicity in Fowl Adenovirus. *J Virol* (2021) 95:e006321. doi: 10.1128/jvi.006321-20

21. Mu Y, Xie Q, Wang W, Lu H, Lian M, Gao W, et al. A Novel Fiber-1-Edited and Highly Attenuated Recombinant Serotype 4 Fowl Adenovirus Confers Efficient Protection Against Lethal Challenge. *Front Vet Sci* (2021) 8:759418. doi: 10.3389/fvets.2021.759418

22. Xie Q, Cao S, Zhang W, Wang W, Li L, Kan Q, et al. A Novel Fiber-2-edited Live Attenuated Vaccine Candidate Against the Highly Pathogenic Serotype 4 Fowl Adenovirus. *Vetsci* (2021) 52:61. doi: 10.1186/s13567-021-00932-y

23. Shah MS, Ashraf A, Rahman M, Khan MI, Qureshi JAA. Subunit Vaccine Against Hydropericardium Syndrome Using Adenovirus Penton Capsid Protein. *Vaccine* (2012) 30:7513–6. doi: 10.1016/j.vaccine.2012.10.013

24. Aziz F, Tufail S, Shah MA, Salahuddin Shah M, Habib M, Mirza O, et al. In Silico Epitope Prediction and Immunogenic Analysis for Penton Base Epitope-Focused Vaccine Against Hydropericardium Syndrome in Chicken. *Virus Res* (2019) 273:197750. doi: 10.1016/j.virusres.2019.197750

25. Schachner A, Marek A, Jaksuliska B, Bilic I, Hess M. Recombinant FavD-4 Fiber-2 Protein Protects Chickens Against Hepatitis-Hydropericardium Syndrome (HHS). *Vaccine* (2014) 32:1086–92. doi: 10.1016/j.vaccine.2013.12.056

26. Shah MS, Ashraf A, Khan MI, Rahman M, Habib M, Qureshi JA. Molecular Cloning, Expression and Characterization of 100K Gene of Fowl Adenovirus for Prevention and Control of Hydropericardium Syndrome. *Biologicals* (2016) 44:19–23. doi: 10.1016/j.biologicals.2015.10.002

27. Wang X, Tang Q, Chu Z, Wang P, Luo C, Zhang Y, et al. Immune Protection Efficacy of FavD-4 Surface Proteins fiber-1, fiber-2, Hexon and Penton Base. *Virus Res* (2018) 245:1–6. doi: 10.1016/j.virusres.2017.12.003

28. Ruan S, Zhao J, Yin X, He Z, Zhang GA. Subunit Vaccine Based on Fiber-2 Protein Provides Full Protection Against Fowl Adenovirus Serotype 4 and Induces Quicker and Stronger Immune Responses Than an Inactivated Oil-Emulsion Vaccine. *Infect Genet Evol* (2018) 61:145–50. doi: 10.1016/j.meegid.2018.03.031

29. Chen L, Yin L, Zhou Q, Li Q, Luo Y, Xu Z, et al. Immunogenicity and Protective Efficacy of Recombinant Fiber-2 Protein in Protecting SPF Chickens Against Fowl Adenovirus 4. *Vaccine* (2018) 36:1203–8. doi: 10.1016/j.vaccine.2018.01.028

30. Yin D, He L, Zhu E, Fang T, Yue J, Wen M, et al. A Fowl Adenovirus Serotype 4 (Fadv-4) Fiber2 Subunit Vaccine Candidate Provides Complete Protection Against Challenge With Virulent FavD-4 Strain in Chickens. *Vet Microbiol* (2021) 263:109250. doi: 10.1016/j.vetmic.2021.109250

31. Wang X, Tang Q, Qiu L, Yang Z. Penton-dedicated Fowl Adenovirus Serotype 4 as a Vaccine Candidate for the Control of Related Diseases. *Vaccine* (2019) 37:839–47. doi: 10.1016/j.vaccine.2018.12.041

32. Jia Z, Ma C, Yang X, Pan X, Li G, Ma D. Oral Immunization of Recombinant Lactococcus Lactis and Enterococcus Faecalis Expressing Dendritic Cell Targeting Peptide and Hexon Protein of Fowl Adenovirus 4 Induces Protective Immunity Against Homologous Infection. *Front Vet Sci* (2021) 8:632218. doi: 10.3389/fvets.2021.632218

33. Hu J, Li G, Wang X, Cai L, Rong M, Li H, et al. Development of a Subunit Vaccine Based on Fiber2 and Hexon Against Fowl Adenovirus Serotype 4. *Virus Res* (2021) 305:198552. doi: 10.1016/j.virusres.2021.198552

34. Tufail S, Shah MA, Zafar M, Asif TA, Shehzad A, Shah MS, et al. Identification of Potent Epitopes on Hexon Capsid Protein and Their Evaluation as Vaccine Candidates Against Infections Caused by Members of Adenoviridae Family. *Vaccine* (2021) 39:3560–64. doi: 10.1016/j.vaccine.2021.05.023

35. Arnone CM, Polito VA, Mastronuzzi A, Carali A, Diomedici FC, Antonucci L, et al. Oncolytic Adenovirus and Gene Therapy With EphiA2-BiTE for the Treatment of Pediatric High-Grade Gliomas. *J Immunother Cancer* (2021) 9:e01930. doi: 10.1159/jitc-2020-001930

36. Zhi FC, Wurie AH, Hou LH, Liang Q, Li YH, Russell JB, et al. Safety and Immunogenicity of a Recombinant Adenovirus Type-5 Vector-Based Ebola Vaccine in Healthy Adults in Sierra Leone: A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial. *Lancet* (2017) 389:621–28. doi: 10.1016/S0140-6736(16)32617-4
48. Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, et al. A Single Dose of an Adenovirus-Vectored Vaccine Provides Protection Against SARS-CoV-2 Challenge. *Nat Commun* (2020) 11:4081. doi: 10.1038/s41467-020-17972-1

49. Pan Q, Wang J, Gao Y, Cui H, Liu C, Qi X, et al. The Natural Large Genomic Deletion Is Unrelated to the Increased Virulence of the Novel Genotype Fowl Adenovirus 4 Recently Emerged in China. *Viruses* (2018) 10:494. doi: 10.3390/v10090494

50. Yan B, Zou X, Liu X, Zhao J, Zhang W, Guo X, et al. User-Friendly Reverse Genetics System for Modification of the Right End of Fowl Adenovirus 4 Genome. *Viruses* (2020) 12:301. doi: 10.3390/v12030301

51. Pei Y, Corredor JC, Griffin BD, Krell PJ, Nagy E. Fowl Adenovirus 4 (Fadv-4)-Based Infectious Clone for Vaccine Vector Development and Viral Gene Function Studies. *Viruses* (2018) 10:97. doi: 10.3390/v10020097

52. Pan Q, Zhang Y, Liu A, Cui H, Gao Y, Qi X, et al. Development of a Novel Avian Vaccine Vector Derived From the Emerging Fowl Adenovirus 4. *Front Microbiol* (2021) 12:780978. doi: 10.3389/fmicb.2021.780978

53. Zhang Y, Liu A, Jiang N, Qi X, Gao Y, Cui H, et al. A Novel Inactivated Bivalent Vaccine for Chickens Against Emerging Hepatitis-Hydropericardium Syndrome and Infectious Bursal Disease. *Vet Microbiol* (2022) 266:109375. doi: 10.1016/j.vetmic.2022.109375

54. Lu H, Xie Q, Zhang W, Zhang J, Wang W, Lian M, et al. A Novel Recombinant FAdV-4 Virus With Fiber of FAdV-8b Provides Efficient Protection Against Both FadV-4 and Fadv-8b. *Viruses* (2022) 14:376. doi: 10.3390/v14020376

55. De Luca C, Schachner A, Heidl S, Hess M. Vaccination With a Fowl Adenovirus Chimeric Fiber Protein (crecFib-4/11) Simultaneously Protects Chickens Against Hepatitis-Hydropericardium Syndrome (HHS) and Inclusion Body Hepatitis (IBH). *Vaccine* (2022) 40:1837–45. doi: 10.1016/j.vaccine.2022.01.060

56. Tian KY, Guo HF, Li N, Zhang YH, Wang B, et al. Protection of Chickens Against Hepatitis-Hydropericardium Syndrome and Newcastle Disease With a Recombinant Newcastle Disease Virus Vaccine Expressing the Fowl Adenovirus Serotype 4 Fiber-2 Protein. *Vaccine* (2020) 38:1989–97. doi: 10.1016/j.vaccine.2020.01.006

**Conflict of Interest:** The authors declare that the research was conducted without potential commercial or financial relationships construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2022 Liu, Zhang, Cui, Wang, Gao and Pan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*